Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons

Jin Woo Kim, Mi Kyung Kwak, Jeong Joon Han, Sung Tak Lee, Ha Young Kim, Se Hwa Kim, Junho Jung, Jeong Keun Lee, Young Kyun Lee, Yong Dae Kwon, Deog Yoon Kim

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Antiresorptives are the most widely prescribed drugs for the treatment of osteoporosis. They are also used in malignant bone metastases, multiple myeloma, and Paget's disease, and provide therapeutic efficacy on those diseases. However, it was reported that the occurrence of osteonecrosis of the jaw (ONJ) could be related to antiresorptive exposures, and there have been many cases regarding this issue. Therefore, a clearer definition and treatment guidelines were needed for this disease. The American Society for Bone and Mineral Research and the Amnerican Association of Oral and Maxillofacial Surgeons reported statements on bisphosphonate-related ONJ (BRONJ), and a revised version was recently presented. In the revised edition, the diagnosis BRONJ was changed to medication-related ONJ (MRONJ), which reflects consideration of the fact that ONJ also occurs for denosumab, a bone resorption inhibitor of the receptor activator of the nuclear factor-κB ligand antibody family, and bevacizumab, an anti-angiogenesis inhibitor. The Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons had collectively formed a task force for the preparation of an official statement on MRONJ based on a previous position paper in 2015. The task force reviewed current knowledge and coordinated dental and medical opinions to propose the guideline customized for the local Korean situation.

Original languageEnglish
Pages (from-to)279-296
Number of pages18
JournalJournal of Bone Metabolism
Volume28
Issue number4
DOIs
StatePublished - Nov 2021

Keywords

  • Bisphosphonate-associated osteonecrosis of the jaw
  • Bone density conservation agents
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons'. Together they form a unique fingerprint.

Cite this